In the published article, “Dobbs et al., 2022” was cited incorrectly in the article. The citation has now been inserted at the correct location in the section, “Methods to find off-targets sites in genome editing applications”, paragraph three, and should read: “These methods vary widely in their approach and even starting material, using cell-free genomic DNA in vitro(https://www.frontiersin.org/articles/10.3389/fgeed.2022.1050507/full;https://www.frontiersin.org/articles/10.3389/fgeed.2022.1050507/full;https://www.frontiersin.org/articles/10.3389/fgeed.2022.1050507/full;https://www.frontiersin.org/articles/10.3389/fgeed.2022.1050507/full;https://www.frontiersin.org/articles/10.3389/fgeed.2022.1050507/full), in intact live cells ex vivo (Crosetto et al., 2013; Tsai et al., 2015; Yan et al., 2017; Wienert et al., 2019; 2020; Zhu et al., 2019; Dobbs et al., 2022), and in vivo animal models (Akcakaya et al., 2018; Wienert et al., 2019; Liang et al., 2022).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
gene therapy, off-target activity, in vivo delivery, genome editing, CRISPR/Cas9, next-generating sequencing
Citation
Wienert B and Cromer MK (2023) Corrigendum: CRISPR nuclease off-target activity and mitigation strategies. Front. Genome Ed. 4:1112956. doi: 10.3389/fgeed.2022.1112956
Received
30 November 2022
Accepted
02 December 2022
Published
20 January 2023
Volume
4 - 2022
Edited and reviewed by
Ayal Hendel, Bar-Ilan University, Israel
Updates
Copyright
© 2023 Wienert and Cromer.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: M. Kyle Cromer, kyle.cromer@ucsf.edu
This article was submitted to Genome Editing in Blood Disorders, a section of the journal Frontiers in Genome Editing
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.